What we should know about treating Corona patients with plasma l 4 hours ago Treating Covid-19 patients with plasma Sky News Arabia - Abu Dhabi The United States recently allowed blood plasma transfusion from people who have recovered from "Covid-19" disease to patients who are treating the fatal disease in the hospital. The US method raised a number of questions: Is this treatment effective and safe? Or is it allowed for political reasons? What is plasma treatment? When someone is infected with Covid-19 disease, caused by infection with the new Coronavirus, their body produces antibodies to fight the virus. The antibodies are concentrated in the plasma, the liquid part of the blood, according to Agence France-Presse. The treatment, which was allowed by the United States on Sunday, is to take antibodies from people who were infected but who have recovered, so-called "convalescent plasma", and injected into patients. This method was first tried in 1892 to combat diphtheria, then against the Spanish flu in 1918. Related news AstraZeneca begins a trial of a treatment for Covid-19 by antibodies 6 prominent treatments for Corona so far .. know it is safe? There is no definitive answer until now to this question, but the initial results seem encouraging. Last June, the American Mayo Clinic Network of Hospitals continued plasma transfusions in a group of 20,000 patients and noticed a very low rate of known side effects. "We concluded that convalescent plasma was safe to use," said Dr. Scott Wright, who conducted the study. Is it effective? On the issue of its effectiveness, all experts agree that more clinical trials are needed to compare plasma with known standard care methods. "In some cases, the results indicated benefits were recorded, but they were not conclusive," said Dr. Sumiya Swaminathan, chief scientist at the World Health Organization. Another study from the Mayo Clinic suggested that plasma helped reduce mortality in patients when they were injected early and antibody levels were high, but the study, which was not clinical, had yet to undergo peer review and did not use a placebo. Researchers at Johns Hopkins University are conducting a parallel study in which plasma is used to try to immunize patients against the Corona virus before they become sick. Dr. David Sullivan, who oversaw the trial, compared it to a near "immediate vaccine". He told France Press that if the results are conclusive, "we can inform people at high risk that they can get treatment early and that they do not have to worry about going to hospital." But this option, if proven effective, cannot be used widely. Some scientists believe that it will be crucial to develop synthetic antibodies, called monoclonal antibodies, that are easily distributed widely. Related news, "Trump's breakthrough" ... What does the "blood serum" do for Corona patients? Treatment with blood plasma .. What happens in Egypt? Was it allowed to be used for political reasons? Political commentators have questioned the timing of the US Food and Drug Administration's permission to use this treatment just two months before the US presidential election, and while Donald Trump is under criticism for managing the health crisis and appears to lag behind his Democratic rival in opinion polls. At the end of March, the US Food and Drug Administration had already urgently authorized the use of chloroquine and hydroxychloroquine, two treatments that the US president had advocated. But the permission was withdrawn after warnings of their side effects on the heart, and after extensive studies showed that they were ineffective against Covid-19. In announcing Sunday to authorize the use of plasma therapy, Trump, as well as the Medicines Agency, introduced a key statistic misrepresented, stating that the plasma had reduced the death rate by 35 percent. A FDA spokeswoman later explained that the number actually indicated a lower risk of death for people who received high levels of the antibodies in the Mayo Clinic study,
compared to those who received low levels. Even FDA Director Dr. Stephen Hahn apologized for misrepresenting the meaning of this number. "I have been criticized for the statements I made on Sunday evening about the benefits of convalescent plasma. The criticism is completely justified. What I should have said is that the data shows a relatively lower risk, not an absolute reduction in risk," the official said in a tweet on Monday evening. . And Dr. Matthew Haynes, who worked in the Ministry of Health under the administration of former President Barack Obama, denounced the matter, saying, "This undermines the credibility of the entire US government." But Dr. Daniel Hanley, who heads the clinical trials at Johns Hopkins University, confirmed that the level of results needed to urgently give permission had already been reached.